Bill Text: HI SB2418 | 2014 | Regular Session | Introduced
Bill Title: Medical Marijuana; High Cannabidiol Products
Spectrum: Partisan Bill (Democrat 3-0)
Status: (Introduced - Dead) 2014-01-21 - Referred to HTH, JDL. [SB2418 Detail]
Download: Hawaii-2014-SB2418-Introduced.html
THE SENATE |
S.B. NO. |
2418 |
TWENTY-SEVENTH LEGISLATURE, 2014 |
|
|
STATE OF HAWAII |
|
|
|
|
|
|
||
|
A BILL FOR AN ACT
RELATING TO MEDICAL USE OF MARIJUANA.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
SECTION 1. The legislature finds that high cannabidiol and tetrahydrocannabinolic acid medical grade products are not psychoactive or hallucinogenic and contain less tetrahydrocannabinol than marijuana strains in Hawaii. Tetrahydrocannabinol is the psychoactive component in the cannabis plants. Empirical evidence indicates that high cannabidiol oils are effective in the treatment of severe medical conditions related to seizures for children with severe forms of epilepsy such as Dravet syndrome and other medical illnesses. At least one supporter of the use of cannabis products with trace tetrahydrocannabinol and high amounts of cannabidiol attests that high cannabidiol tinctures have no potential for abuse.
The legislature finds that eventually Hawaii residents would be able to go to purchase from another state high cannabidiol and tetrahydrocannabinolic acid medical grade products and bring them back to Hawaii. The legislature finds that families should not need to relocate to another state to acquire these high cannabidiol products.
The purpose of this Act is to include the medical use of certain substances as allowable medical uses of marijuana for limited purposes.
SECTION 2. Section 329-121, Hawaii Revised Statutes, is amended by amending the definitions of "marijuana" and "medical use" to read as follows:
""Marijuana"
shall have the same meaning as "marijuana" and "marijuana
concentrate" as provided in sections 329-1 and 712‑1240[.] and
shall include various forms of
non-psychoactive, high cannabidiol products, such as alepsia, charlotte's web, phoenix
tears, AC/DC (a phenotype of the cannatonic strain with
a 22 to 1 cannabidiol to tetrahydrocannabinol ratio), and avidekel, that do not
contain a significant amount of tetrahydrocannabinol.
"Medical use" means the acquisition, possession, cultivation, use, distribution, or transportation of marijuana or paraphernalia relating to the administration of marijuana to alleviate the symptoms or effects of a qualifying patient's debilitating medical condition. For the purposes of "medical use", the term distribution is limited to the transfer of marijuana and paraphernalia. In the case of high cannabidiol products, "medical use" means the use of various forms of non-psychoactive, high cannabidiol products that do not contain a significant amount of tetrahydrocannabinol, to alleviate symptoms of seizures, cancer, post-traumatic stress disorder, severe epilepsy in children, and chronic illnesses."
SECTION 3. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.
SECTION 4. This Act shall take effect on January 2, 2015.
INTRODUCED BY: |
_____________________________ |
|
|
Report Title:
Medical Marijuana; High Cannabidiol Products
Description:
Includes the medical use of certain substances as allowable medical uses of marijuana for limited purposes. Takes effect 1/2/2015.
The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.